


Big Idea
CONNECTpreneur



NETWORKING & PITCH

EXTRAVAGANZA

One of the world's best tech networking events!



FEBRUARY 6, 2025

8 AM - 12 NOON



BWTECH@UMBC SOUTH

CONNECTPRENEUR.ORG

Agenda

8:00 - 9:00 am - REGISTRATION / NETWORKING

9:00 - 9:30 am - WELCOME REMARKS

TIEN WONG, CEO, Opus8; Founder, Big Idea CONNECTpreneur Forum

AARON MISCENICH, Executive Director, bwtech@UMBC

JOHN GILSTRAP, Assistant Secretary of Commerce, Maryland Department of Commerce

PAT SHERIDAN, Co-Founder and Managing Partner, Modus Create

ANTHONY MILLIN, Founder and Chair, NEXT powered by Shulman Rogers

9:30 - 10:45 am - COMPANY SHOWCASE / ROCKET PITCH

Promising Early Stage Companies will be introduced by:

- SARA CLASPER Associate Attorney, NEXT powered by Shulman Rogers

- DEBBIE CLINE Founder and Chief of Customer Success , Buzzy Rocket

PRESENTING COMPANIES

ACTA Thermal Technologies - Gib Dunham

Astek Diagnostics - Mustafa Al-Adhami

ColdSnap - Matthew Fonte

ezVOLTz.com - Sam Malhotra

Coagulation Sciences - Sheldon Goldstein

Fzata, Inc. - Elizabeth Smith, PhD MBA

ICaPath - John Kennedy

Nataur - Francesca Gallucci

PredxBio - Dusty Majumdar, PhD

Propel IOT - Rick Burtner

Ridealike - Zelani Bhuyian

TESS Energy Solutions - Michael Logan

10:45 - 12:00 pm - NETWORKING

Speakers



TIEN WONG, CEO, OPUS8, INC.

Mr. Tien Wong is a tech investor, entrepreneur, and CEO. He is Chairman & CEO of Opus8, Inc., a private investment and advisory firm investing in exceptional life science and tech enabled services companies, as well as specializing in raising capital for promising tech companies and alternative investment fund managers. He is Founder of CONNECTpreneur, a global community of 25,000+ founders, investors, CEOs, and business leaders. CONNECTpreneur organizes the world's largest monthly virtual investor pitch events as well as in-person Forums with upwards of 500 attendees, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Since 2012, over 1200 companies have presented, half of whom have received funding from investors from the CONNECTpreneur investor network. Mr. Wong is also a Venture Partner in IronGate Capital Advisors, a VC and Fund of Funds manager investing in dual use technologies; Investment Advisory Board member of Virginia Venture Partners; and Chairman of Lumious, an ed tech company which provides learning & development services to Fortune 500 customers.



AARON MISCENICH, EXECUTIVE DIRECTOR, bwtech@UMBC

Since joining bwtech as Executive Director in 2019, Aaron Miscenich has been a driving force behind Maryland's growing tech ecosystem. With decades of experience guiding companies from inception to maturity, Aaron brings unparalleled expertise in fostering entrepreneurship and innovation. In his native Louisiana, he spearheaded initiatives to build a knowledge-based economy through diverse funding streams and public-private partnerships. At bwtech, Aaron leads efforts to expand its role as a thriving hub where innovation, business, and entrepreneurship converge, fostering economic growth and opportunity across Maryland.



PAT SHERIDAN, CO-FOUNDER & MANAGING PARTNER, MODUS CREATE

Pat is focused on the intersection of design, technology, and business. He saw the need for a high-end product consulting firm built with open-source team design and the concept for Modus was born. Pat helps clients see new ways to tackle challenges with emerging technology and brings his unmatched passion to work every day. As a serial entrepreneur and active startup mentor, he's a co-organizer of NoVa.JS and NYC.JS. He is a 2011 graduate of Mind Share, received his MBA from Georgetown University, where he is currently an Entrepreneur-in-Residence, and holds a BFA from the Corcoran College of Art and Design, where he currently serves as an advisory council member for the George Washington University Columbian College of Arts and Sciences.



JOHN GILSTRAP, ASSISTANT SECRETARY OF COMMERCE, MARYLAND DEPARTMENT OF COMMERCE

John Gilstrap serves as the Assistant Secretary under the Division of Innovation and Growth at the Maryland Department of Commerce. In this role, he collaborates with Deputy Secretary Ricardo Benn to oversee key offices, including the Office of International Investment and Trade, the Office of Military and Federal Affairs, and the Office of Strategic Industries. Their collective efforts aim to develop and implement strategies that foster innovation and entrepreneurship within the state. Prior to his current position, Gilstrap was a business executive in various organizations across the region. His extensive experience in real estate, community development, and educational technology has equipped him with a robust background that he brings to the Department of Commerce. Gilstrap has over 20 years of experience in operations, strategic planning and leadership, with extensive experience in policy, research and analysis, economic development, and AI innovation. Spending most of his career in New York City, he was most recently the principal consultant at NorthStar AI Rising Corp. He also co-founded and was the managing director of Hudson Cannabis LLC and previously served as the executive vice president at Empire State Development Corp.

Speakers



ANTHONY MILLIN, NEXT CHAIR, PARTNER, SHULMAN ROGERS

Anthony Millin is a trusted legal and business advisor to startup and emerging growth companies. As a startup attorney, a serial entrepreneur, a former seed stage venture partner, and the Founder and Co-Chair of NEXT powered by Shulman Rogers, named in 2024 as the nation's top law firm for "Enabling Startup Success" by LegalWeek, Anthony brings his unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund raising process, and to address the legal issues faced by a startup. This background provides him with valuable insights into the legal and business needs of his clients. Within Shulman Rogers, his unique skill set has earned him an appointment as Chair of Shulman Rogers' Strategic Advisory Committee. A creative problem solver and strong advocate dedicated to the success of his clients, Anthony frequently serves as his clients' "outside general counsel, taking a leadership role in managing the full range of their legal needs from formation and financings to growth and exit. Anthony is a frequent public speaker on topics impacting startup and emerging growth companies. Anthony is also a Co-founder and CEO of My NEXT Raise, an investor readiness platform and Co-Founder and Senior Strategic Advisor of RT Energy.



SARA CLASPER, ASSOCIATE, NEXT POWERED BY SHULMAN ROGERS

Through the NEXT platform, she typically represents early-stage seed and emerging growth companies and helps position them for success. Sara advises local and national companies on private equity, venture capital transactions, mergers and acquisitions, compliance issues, capital raises, equity compensation and other general corporate matters.

Sara effectively balances efficiency with risk mitigation in her deal transactions. Prior to her work with NEXT, Sara spent 6 years as a persuasive litigator, honing her problem solving and negotiation skills and deepening her understanding of the type of contractual provisions that can eventually lead to disputes. This unique background for a transactional attorney enables her to anticipate the potential hurdles that a business transaction may encounter and foresee the importance and implications of each element of a deal during negotiations.




DEBBIE CLINE, FOUNDER & CHIEF OF CUSTOMER SUCCESS, BUZZY ROCKET

Debbie is co-founder, chief of customer success at Buzzy Rocket and yellow lab lover. From LA to London, she is well known as an expert in creating that certain elusive magic that drives explosive growth at the intersection of companies and customers. She has proven strategic vision, and isn't afraid to get in the trenches. In fact, she's been doing this at companies big and small for 25+ years. Her background includes executive level positions at both public companies and startups where she has proven over and over again that her passion, drive and results oriented perspective get it done. She is tenacious, loves the game changer and loves to win.

ACTA TECH US, INC.

Breakthrough cooling and heating




OVERVIEW

ACTA has a cooling and heating device which is highly efficient, uses no toxic chemicals, has no moving parts and will operate for decades with little or no maintenance.

THE PROBLEM

Compressor based coolers use Freon which is a toxic gas, and they have very poor reliability.



OUR SOLUTION

A thermo-electric cooler (TEC) which (i) uses no Freon, (ii) is over 40% more energy efficient and (iii) is solid state.



BENEFITS

Environmental

- No chemicals
- 40% more efficiency
- Closed loop

Intelligent design

- Cooling and heating
- Modular
- Infinitely variable
- Solid state

Smart approach

- Silent
- Light weight
- Long life
- Semiconductor based



MARKET OPPORTUNITY

*10 new air conditioners
will be sold every second
over the next 30 years
(= 9.4 billion units)*

End Markets: HVAC | Auto | Food & beverage | Transportation

5 KEY INNOVATIONS

TIMELINE

2023

Q4: Patent filed / Pre-Seed capital

2024

Q1: First Revenue / customer contract

Q2: TEC optimization / seed Round

Q3: Gen 3 Prototype

Q4: Closed Seed Round

2025

Q1: Gen 4 Prototype / File new IP

Q2: Lab testing

Q3: Customer demonstrations

Q4: Commercial sales

TRACTION

- ✓ Key patent filed
- ✓ First revenue
- ✓ Gen 4 prototype


FUNDING

Round	Amount	Timing	Status
Pre-Seed Round	\$250k	Q4 2023	Closed
Seed Round	\$700k	Q4 2024	Closed
A Round	\$5mm	Q2 2025	Launching

CONTACT

Gib Dunham
 e. gib.dunham@acta-techus.com
 t. 646-470-1548
 www.acta-techus.com

FINANCIALS



Value Proposition

Company Background: Astek Diagnostics is a precision diagnostics company focused on revolutionizing antibiotic sensitivity testing through its Jiddu Analyzer platform. Initially targeting urinary tract infections (UTIs), the Jiddu Analyzer delivers UTI diagnosis and antibiotic sensitivity results within one hour, addressing the critical issues of antimicrobial resistance and delayed treatment. With successful pilots, including partnerships with MedStar Health, the company is poised to enter the market in 2025.

Leadership Team:

- Mustafa Al-Adhami, CEO: Experienced in building and scaling startups.
- Chris Skipwith, Chief Science Officer: Leads scientific development.
- Scott O'Brien, Chief Commercial Officer: Oversees commercialization strategies.
- Courtney Cavin, Chief Product Officer: Drives product innovation and delivery.
- Suzanne Groah, MD, Chief Medical Officer: Provides medical/research leadership.

The team is supported by an advisory board with expertise in microbiology, urology, regulatory affairs, and infectious diseases.

Products/Services:

The Jiddu Analyzer fills a critical unmet need by providing rapid, point-of-care UTI diagnostics and antibiotic sensitivity testing. Unlike traditional methods, which take 24-72 hours, the Jiddu delivers actionable results in one hour. Its advantages include high accuracy (95% for antibiotic resistance), affordability, and scalability, positioning it as a game-changer for both patient outcomes and healthcare costs.

Technologies/Special Know-How:

The Jiddu platform is built on patented technologies, including its rapid detection algorithm, fluidic cartridge, and metabolic activity-based testing. These innovations create a significant barrier to entry, as competitors typically rely on slower or less precise methods like culture-based or molecular tests. Ongoing alpha prototype-based clinical studies validate its efficacy, reinforcing its market potential.

Market:

The initial target market is U.S. urology clinics and hospitals, addressing a \$1.6 billion annual cost from mistreated UTIs and a \$3 billion total addressable market across UTIs, bloodstream infections, and other bacterial diagnostics. With 8.1 million UTI-related hospital visits annually in the U.S., Astek's business model includes device sales (\$10/device) and recurring revenue from disposable cartridges (\$50/cartridge).

Astek recently launched an Early Access Program with strategic partners, securing multiple LOIs for early device deployment and data collection. The program provides initial visibility (Year 1 post FDA clearance) to \$30M+ in ARR through collaborations with MedStar Health, Solaris Health Partners, University of Maryland, Golden Gate Urology, HALO Dx, Northwell Health, Johns Hopkins Hospital, and other leading institutions.

Distribution Channels:

Astek will deploy its solution through direct sales to hospitals, urology clinics, and strategic partnerships with major healthcare distributors (e.g., McKesson, Medline, Henry Schein, Cardinal Health, ThermoFisher, etc.).

Competition:

Astek Diagnostics operates in a competitive landscape with solutions like urine dipsticks, which have high false-positive rates (up to 40%), and newer technologies like Sysmex Astrego PA-100 and BacterioScan 216Dx™, which offer faster diagnostics but come with limitations such as handling requirements, slower results, or lack of antibiotic sensitivity testing. Competitors like Llumens Lodestar DX and Savyon Uriscreen address certain diagnostic needs but fall short on comprehensive sensitivity assessments or FDA approvals. In contrast, Astek's Jiddu Analyzer delivers one-hour results for UTI diagnosis and antibiotic sensitivity with a low detection limit (10 CFU/mL), significantly reducing false positives. It combines accuracy, speed, and cost-effectiveness, offering a strain-agnostic solution capable of transforming point-of-care and clinical diagnostics.

Quick Facts

Company Name:

Astek Diagnostics, Inc.

Contact:

Mustafa Al-Adhami, CEO

Address:

1450 S Rolling Road
Halethorpe, MD 21227

Phone: 484.459.8258

Email: mustafa@astekdx.com

Website: www.astekdx.com

Industry: Medical
Devices/Diagnostics

Domain: Healthcare

Bank: Fulton Bank

Law Firm: Bowie & Jensen,
LLC

Patent Estate: 4 patents +
favorable FTO opinion

Number of Employees: 7

Leadership Team:

- Mustafa Al-Adhami, CEO
- Chris Skipwith, CSO
- Scott O'Brien, CCO
- Courtney Cavin, CPO
- Suzanne Groah, MD, CMO

Amount of Financing Sought:
\$15M

Current Investors

YC, TEDCO, AYANA,
Wexford, Harvard, Abell,
KeyTech, MMF, etc.

Use of Funds:

Completing the beta prototype,
obtaining FDA clearance,
initiating commercialization

Auditor:

TBU

\$'000

Financial Projections (Unaudited):

	2023	2024	2025	2026	2027
Revenue	444	276	1,654	27,893	89,985
EBITDA	(1,424)	(3,927)	(9,426)	7,383	29,598

ColdSnap

Investment Opportunity Overview

Q1 2025

Our Freeze-on-Demand Machine and Pod Technology is Revolutionizing the Way Premium Ice Cream and Frozen Beverages are Produced, Transported, and Enjoyed Around the World




Company Overview

- ◆ Founded in 2018, ColdSnap is revolutionizing the way ice cream and frozen beverages are produced, transported, and enjoyed around the world
- ◆ Pod-based, freeze-on-demand technology provides premium single-serve frozen treats in as little as ~2 minutes
- ◆ Shelf-stable pods negates the cold supply chain associated with shipping and storing frozen treats
- ◆ Broad array of delicious, premium frozen snacking products including ice cream, non-dairy desserts, Snappuccino® frozen lattes, frozen smoothies, frozen protein shakes, frozen cocktails, and boozy ice cream
- ◆ Secured intellectual property – 108 issued patents, 42 trademarks, and 78 patent applications pending
- ◆ Exponentially scalable growth opportunity across an enormous \$105B+ global ice cream & frozen beverage market
- ◆ State-of-the-art, 70,000 sq. ft. pod production and warehouse facilities with in-house research & development team
 - ◆ Capacity to produce 45M pods per year
- ◆ HQ: Billerica, Massachusetts



			
No Water Needed	No Prep Time	Ready in ~2 Minutes	No Mess, No Fuss
			
Deliciously Smooth	Health-Conscious	Real-Time Insights	Eco-Friendly Pods

[Click Here to Witness the ColdSnap Revolution!](#) 

Select Product Portfolio

			
Premium Ice Cream	Non-Dairy Frozen Desserts	Snappuccino® Frozen Lattes	
			
Frozen Smoothies	Frozen Protein Shakes	Frozen Cocktails	Boozy Ice Cream

~\$8M

2025E Revenue

158%

2025E-29P Revenue CAGR

\$332M

2029P Revenue


43%

2029P EBITDA Margin



The Future of EV Charging Management
electrifying mobility, simplifying charging

Contact Information:

 **Website:** ezvoltz.com

 **Email:** info@ezvoltz.com

 **Location:** Annapolis, MD

Company Overview:

ezVOLTz.com (ezVOLTz) is a premier **EV Charging Managed Service Provider** that specializes in the management, governance, and optimization of EV charging ecosystems for enterprise clients, government entities, and fleet operators. We bridge the gap left by traditional players by deploying an AI-based platform to manage complex EV charging ecosystems.

Our Solutions:

- **ezCONNECT™:** Our proprietary AI-based backend charger management software that integrates with any API to provide real-time monitoring, analytics, and dynamic pricing solutions.
- **ezVOLTz App:** A nationwide trip-planning and charging network application available on the **Apple App Store** and **Google Play Store**, to enhance driver experience and generate ad revenue.
- **Charger Network Operations Center (CNOC):** A **24/7/365** command center that ensures uptime, predictive maintenance, and SLA-based support for all charging assets.
- **Flexible Pricing & Monetization:** Tiered pricing models enable differentiated rates for county residents, veterans, and transient EV drivers.
- **End-to-End Support:** From installation to ongoing maintenance, including partnerships with ProKey for ABB-certified repairs.

Why ezVOLTz?

- ✓ Winner of the NASPO EV Charging Station Equipment/Services Nationwide Contract
- ✓ Enterprise-Grade Managed Services for multi-site and multi-brand charger fleets
- ✓ Government & Fleet Expertise with active contracts in multiple states
- ✓ Innovative Software & Monetization through integrated platforms
- ✓ Strong Leadership & Advisory Board with expertise in mobility, energy, and smart infrastructure

Investment Opportunity:

ezVOLTz is poised for rapid expansion as the demand for EV infrastructure skyrockets. We have already raised **\$900K in a friends & family round** and are currently seeking strategic investors to scale our technology, operations, and market penetration.

Leadership Team:

- **Sam Malhotra** – Chief Executive Officer
- **John Gillespie** – Chief Revenue Officer
- **Ken Nelson** – Chief Financial Officer
- **Sean Powell** – VP, State & Local Govts
- **Kelley Gillespie** – Chief Marketing Officer
- **Laura Everngam-Price** – Director of Strategic Partnerships

The EV charging industry is at an inflection point, and ezVOLTz is positioned to lead the transformation from installation to long-term reliability and scalability. With a proven model, cutting-edge technology, and a rapidly growing market, we're addressing the most critical pain points in EV charging. This is your opportunity to invest in a company filling the gaps others have ignored, driving innovation, and unlocking a \$100B+ market opportunity. Join us in powering the future of EV charging infrastructure – together, we can dominate this space.



COAGULATION SCIENCES

Breakthrough in Blood Transfusion Management

INTRODUCTION/ ONE-PAGE EXECUTIVE SUMMARY

Clinical Problem: Research indicates 40% - 59% of blood transfusions are unnecessary. This results in needless complications such as allergic reactions, lung injury, fluid overload, immune system damage resulting in infections, prolonged hospitalization, and shortened lifespan. Hospitals lose approximately \$800 for each unit transfused in the inpatient setting while insurance companies lose billions annually.

Unmet Need: Unnecessary transfusions occur most often during major bleeding. With existing diagnostic tests, it is difficult to determine which blood products to transfuse, in what amount, and even whether blood products are indicated at all. Limitations of existing tests include prolonged time to results, complex and cognitively challenging interpretation, non-specific information and minimal, if any, treatment guidance. There is an unmet need for an easy-to-use test to guide blood transfusion decisions. Key opinion leaders, blood bank directors, surgeons and anesthesiologists confirm the need for Coagulation Sciences' Multiple Coagulation Test System (MCTS).

The Solution: Coagulation Sciences has developed the Multiple Coagulation Test System (MCTS™). The system performs 12-18 blood tests simultaneously, in a disposable cartridge, in approximately 10 minutes, at the point-of-care. It determines which treatments will stop bleeding. No other platform provides this information. Also, MCTS results are extremely easy to interpret.

Unique Selling Advantage: The fully-automated MCTS provides more useful information to guide transfusion than existing tests, and does so in ~ 10 mins.

Business Model: The MCTS is a platform, with a razor-blade business model. Addition of new therapies to the disposable cartridge can expand use from cardiac surgery to trauma and transplant surgery, post-partum hemorrhage, and assessment of anticoagulants in doctors' offices. Revenue in year three of sales is projected to reach \$75M.

The Market: The global coagulation testing market is projected to reach \$7.88 billion by 2032. The MCTS will not simply enter the point-of-care market, but will at times also replace tests currently performed in hospitals' laboratories and doctors' offices, such as the PT/INR and APTT.

Research to Date: In-vitro research validates the underlying technology. Currently, treatment is often empiric, as factor levels cannot be performed quickly. The MCTS provides more information than factor levels in ~ 10 minutes. Research at the Mayo Clinic confirms the relationship between coagulation factor deficiencies and bleeding after cardiac surgery, and results from the study will be used to improve the MCTS and build the GMP-platform.

Intellectual Property: Coagulation Sciences holds seven unique patents.

Summary: Doctors often select a treatment for bleeding based on an abnormal blood test result, but most tests are non-specific and can require too much time, while some are difficult to interpret. MCTS results are available rapidly and are easy-to-interpret, and will aid physicians in the management of bleeding patients, improving patient outcomes and decreasing costs.

For information contact: Sheldon Goldstein MD, CEO
sgoldstein@coagulationsciences.com 917-363-6542
4700 Independence Ave. Riverdale, NY 10471



Pioneering Yeast Oral Biologics

OVERVIEW Fzata®, Inc. (www.fzata.com) is reaching for the “holy grail” of oral biologics with a first-in-class modality intended for gastrointestinal (GI) -related diseases including gut-health axis disorders. Founded in 2015 and supported with **\$24 MM non-dilutive NIH grants**, Fzata has developed a deep pipeline with **>5 candidates** with validated animal PoC. Orally administered live recombinant yeast expresses and secretes biologics in the GI, with no anti-drug antibody (ADA) response & no toxicities. **First-in-human clinical trial 2025.**

CHALLENGES of Conventional Biologic Therapies:

1. **Undesirable needle** administration
2. **1/2 day** infusions
3. **Loss of response** due to anti-drug Ab (ADA)
4. Often have **systemic toxicities**
5. **Expensive** due to dev. & mfg. costs
6. **Cold chain** distribution & **short shelf life**

“A pill over a shot would be an absolute dream!”

Aurora D, age 15; IBD

VIDEO



\$24 MM

OUR SOLUTION Fzata's **Bio**engineered **Probiotic Yeast Medicines (BioPYM™)** first-in-class modality address above challenges using a live yeast "factory" encapsulated for oral administration.

PROPRIETARY ORAL BIOLOGICS MODALITY

The BioPYM platform genetically modifies **yeast to function as a micro-factory in the gut** to make therapeutic locally at the disease site. Plug & Play genomic cassette enables a pipeline of protein therapeutics like monoclonal antibodies or enzymes. Yeast is **room temperature stable**.

IBD UNMET NEED

~50% of anti-TNFα IBD Patients discontinue therapy

FZ006 serves this population

Target Market >\$6B

FZ002 BioPYM efficacious for prevention of primary and recurrent *C. diff* infection; rescues hamster fulminant CDI model. FIH targeted for 2025.

FZ006 BioPYM efficacious in multiple IBD animal models; clinically proven MoA, rescues severe mouse DSS-colitis model co-morbid with CDI. PreIND completed.

LIFE-CHANGING

- Oral, no needles
- No travel to clinic
- No ½ day infusion
- No refrigeration
- Easy to carry



CLINICAL BENEFITS

- Targeted to GI, high efficacy
- No systemic side effects
- Safe for chronic use
- No anti-drug antibody (ADA) response
- No immune suppression
- Antibiotic co-administration OK
- No trough/peak
- Microbiota support

MFG SAVINGS

- Plug & play
- Very low yeast COGs
- Robust, scalable
- No downstream protein purification
- Cross over efficiencies among BioPYM candidates

CONTACT

Dr. Elizabeth Anne Smith
Halethorpe, Maryland, 21227 USA
www.fzata.com +1.240.904.5127
Elizabeth_Smith@fzata.com



CONTACT INFO



© Fzata, 2025

RAISING SERIES A \$10 MM

FZ006 cGMP Mfg: \$4 MM
Pipeline \$1 MM
G&A: \$5 MM
Funding duration = 2 years

MISSION

Expand safety, efficacy & access for therapeutic biologics leveraging oral administration

GI INDICATIONS

FZ002: *C. diff* infection
• 2025 First-in-human P1
• NIH Supported

FZ006: IBD

- preIND 2024

Pipeline: infectious diseases, inflammatory diseases, diabetes/obesity, abdominal pain, stress

FUNDING TO DATE

Founders: \$0.5 MM
Angel: \$1.0 MM
NIH: \$24.0 MM non-dilutive

BUSINESS MODEL

Partner each candidate after phase 1 clinical study. Revenues to Fzata based on upfront, milestones and royalties.

Each indication est. **>\$1B** US annual net sales.

PEER REVIEWED PUBLICATION

Chen K, et al. A probiotic yeast-based immunotherapy against *Clostridioides difficile* infection. *Sci Transl Med.* 2020 Oct 28;12(567).

INTELLECTUAL PROPERTY

Assigned or licensed to Fzata.

LEADERSHIP

CEO: Zhiyong Yang, PhD
CSO: Hanping Feng, PhD
CBO: Elizabeth Smith, PhD, MBA



Executive Summary 2025

Multi-Million-Dollar Licensing Opportunities

Recent transactions:

Company	Licensee	Date	Cash
Genevant Sciences	Tome Biosciences	Jan-24	\$114M
Generation bio	Moderna	Mar-23	\$76M
Beam Therapeutics	Pfizer	Jan-22	\$300M
Genevant Sciences	Takeda	Mar-21	\$600M
Orna Therapeutics	Meck	Aug-22	\$150M

We offer biotech opportunities to leverage our technologies:
Redefine Immunotherapy: Our immune stimulant (IL-12) encapsulated in PLGA nanoparticle does not have traditional toxicity issues associated with cytokine therapies, and our PLGA component provides a delayed release allowing the low dose cytokines to maintain their efficacy over time.

Expand R&D into New Payloads: Our PLGA nanoparticle platform allows for encapsulation of various therapeutics, facilitating development treatments across indications.

Diagnostic Creates Novel Data: Valuable unprecedented novel data improves the development and implementation of a personalized immuno-therapy treatment strategy.

Billion Dollar Addressable Markets

ICaPath’s technologies position us to capture a substantial market share well over \$100 billion in the oncology sector. Since we are the only company delivering immunotherapy by PLGA-nanoparticle encapsulation, our non-toxic and highly effective approach offers a compelling value proposition for patients, healthcare providers and investors.

Competitive Advantages

ICaPath’s PLGA nanoparticle based therapeutic and delivery system outperform traditional immunotherapies by:

Enhanced Stability and Controlled Release: Therapeutic efficacy can be maintained over an extended period, critical for the effective treatment of chronic conditions like cancer.

Improved Biodistribution: PLGA nanoparticles can be engineered to ensure the therapeutic reaches tissues while minimizing off-target effects, including systemic toxicity.

Overcoming Traditional Limitations of Competitors:

Liposome delivery can suffer with stability and variable drug release profiles, of which our PLGA nanospheres do not.

Pegylation may prolong the half-life of cytokines but often at the cost of reduced bioactivity, whereas PLGA nanoparticles avoid this by providing sustained release without altering the bioactivity of the encapsulated cytokine.

Immunocytokines face resistance with targeted moiety, production complexity and immunogenicity, versus our PLGA’s precise cytokine release, thus its efficacy.

Overview

Based at Johns Hopkins Tech Ventures in Baltimore, MD, ICaPath has developed a patented, novel and first in class immunotherapy solution (the “IND”) based on PLGA (polylactic-co-glycolic acid) nanoparticles in order to encapsulate and deliver systemically powerful cytokines (IL-12) in a highly controlled and monitored approach of personalized care that redefines traditional immunotherapy.

The Company is raising \$4.0 million in its first of 2 tranches (total \$7.5 million) to immediately initiate manufacturing and complete its IND for FDA validation. The Company plans to negotiate a licensing agreement during this preclinical period that would fund its ensuing FDA clinical trials for a basket of four metastatic cancers: melanoma, renal cell carcinoma, soft tissue sarcoma and osteosarcoma. Each cancer indication would also generate millions in recurring revenue streams during the FDA clinical trials.

Mission Statement

Improve upon the Current “Treating” Philosophy. For nearly 20 years cancer treatment has focused on targeted therapies to avoid off-site toxicity. The treating philosophy of targeted therapy has seen billions of dollars spent per year over decades in search of that magic bullet for cancer. However, it has only been misguided and totally exhausted.

Novel “Treating” Philosophy and Solution

Our immunotherapy solution will reverse decades of failures using a targeted approach because we have addressed the innate limitations on targeted therapy in immunotherapy:

- **Immunotherapy Approach:** *Systemic immunostimulation.*
- **First-in-Class Therapeutic:** ICP-001 is Interleukin-12 that’s PLGA nanoparticle encapsulated into low doses (LD IL-12). This nano-LD IL-12 redefines immunotherapy by resolving serious toxicity issues while maintaining sustainable immune stimulation with weekly timed releases.
- **First-in-Class Delivery:** Our nano-drug delivery systems (NDDS) encapsulate immunotherapeutic agents in PLGA nanoparticles that allow for controlled and precise delivery.
- **Real-time Diagnosis:** Our proprietary immuno-surveillance platform allows our immunotherapy to be customized based on a patients’ individual immune response to both the cancer and the treatment, during and after (over the entire term).
- **Un-Precedented Novel Data:** Our immuno-surveillance technology generates massive immune profiling data that could engage with AI algorithms to provide expanded medical insights, hereby more effective treatment strategies.



Value Proposition: Nataur's **fermentation-based platform** provides a cost-competitive, environmentally friendly alternative to the traditional petroleum supply chain for sulfur ingredients, reshaping how essential compounds like taurine are produced.

Company Background: Nataur makes sustainable bio-based solutions, that replace petrochemical synthetics. Founded in 2021 to meet consumer demand for sustainable alternatives, the company is backed by patented technology and a global manufacturing partner. Nataur focuses on high-value markets, including supplements, cosmetics, functional beverages, and animal health.

Leadership Team: 70+ years in novel biotechnology commercialization for food, feed, agriculture, and pharma markets with deep experience in GTM and ingredients: Daphne Preuss, CEO; Kathleen Turano, COO; Frank Turano, CRO; and Francesca Gallucci, Head of Commercial

Products: Bio-Taurine: the first product from Nataur's innovative platform. Positioned as the natural and clean alternative that meets global demand for high-purity taurine while addressing significant challenges in the current taurine market. A critical amino acid, taurine plays a key role in brain development, longevity and healthy aging, heart health, microbiome balance, skin health, and pet and animal nutrition.

Technologies/Special Know-How: Nataur's fermentation platform uses safe, proprietary microbes to produce taurine and other sulfur-based ingredients. This clean process avoids fossil fuel dependence and aligns with global sustainability trends. **5 issued patents** with 4 additional patents in prosecution, establishes Nataur as the dominant bio-based sulfur-compound innovator.

Market: The taurine market is valued at \$2.5 billion with a 5.3% CAGR. Emerging applications in human and animal health, as well as opportunities in surfactants, represent an 80% additional \$1-2 billion in potential growth. Bio-Taurine positions Nataur to lead this transformation with a sustainable solution that addresses both current demand and future expansion.

Distribution Channels: B2B; Nataur executes orders from leading global players and our manufacturing partner fills the orders and ships the Bio-Taurine to the customers.

Competition: Currently, 95% chemically synthesized taurine is made from petrochemicals in China in a highly consolidated supply chain. Top Chinese petroleum-based taurine producers: Hubei Grand Fuchi, Jiangyin Huachang, and Qianjiang Yongan.

Quick Facts

Company Name: Nataur

Contact: Daphne Preuss

Address: 1450 S. Rolling Rd,
Baltimore, MD 21227

Phone: 443-543-5582

Email: dpreuss@nataur.com

Website: www.nataur.com

Industry: Biotech

Law Firm: Perkins Coie, LLP

Patent Estate:

US10,092,527

US10,874,625

US11,078,547

US11,220,69

US11,771,114B2

Number of Employees: 5

Leadership Team: Daphne Preuss, Kathleen Turano, Frank Turano, Francesca Gallucci

Amount of Financing

Sought: \$500k in Q1; \$3.5 M follow on

Use of Funds: Commercial Dev., Marketing, Sales, R&D

Financial Projections (Unaudited):

	2025	2026	2027	2028	2029
Revenue (dollars in thousands)	3,580	23,807	53,271	124,731	172,834
EBIT (dollars in thousands)	(1,973)	4,277	13,057	55,520	89,364

EXECUTIVE TEAM

B. Dusty Majumdar, PhD

CEO

Recognized business and commercial leader in Healthcare, Life Sciences and AI

S. Chakra Chennubhotla, PhD

Chief of AI, COO, Co-Founder

Recognized leader in Computational and Systems Biology and Explainable AI

BOARD OF DIRECTORS

Stanley Marks, MD (Chairman)

Chairman of UPMC Hillman Cancer Center

Bill Newlin

Newlin Investment Company

B. Dusty Majumdar, PhD

CEO

S. Chakra Chennubhotla, PhD

Chief of AI, COO, Co-Founder

FINANCIAL INFORMATION

Funding raised until now:

\$14.5M (\$7M non-dilutive)

Current Raise:

- **Now closing \$2M for Series A-2**

(participation preferred stock)

- Up-to \$20M Series B in 2025

USE OF PROCEEDS

Strategic and Technical Hires

Expanding the Spatial Biology ecosystem

World-class go to-marketing strategy

BANK AND LEGAL

PNC Bank, Pittsburgh, PA

TroutmanPepper, Pittsburgh, PA (Corp)

Goodwin Law, Boston, MA (IP)

Empowering Pharma to Accelerate Discovery and Revolutionize Clinical Trials

Today, there are significant challenges in managing cancer patients as available therapies only work for ~20% of the time. Moreover, 90% of the drugs fail to get to the market and it takes on an average 8 years of development. Tumor biology holds the key to predicting response/resistance to therapy.

PredxBio is the only company unraveling the dynamics of the tumor biology from biopsy samples. PredxBio is powering next-generation cancer therapeutics with AI-driven spatial biomarkers, which delves into the mechanism of action of drugs and predicts the patient outcomes with close to 95% accuracy. Over the last 3 years PredxBio has empowered top 10 Pharma companies to accelerate discovery and revolutionize clinical trials across some of the highest mortality cancers. PredxBio's technology will impact the lives of more than 25 million cancer patients around the world.

PredxBio Investment Thesis

- Next generation platform for **derisking drug development** at the intersection of AI, Spatial Biology and Oncology beyond black-box solutions in the market
- Commercial traction with multiple Pharma clients with **current revenue of ~\$1M** from Genmab, AstraZeneca, Amgen, BMS, Abbvie, Kite/Gilead, and Jazz Pharma.
- Seasoned leadership, **100+ years of experience** incl. GE Healthcare, Exact Sciences, ASCO, IBM, Cernostics, Carnegie Mellon University, and UPMC
- Driving significant value for shareholders and **hope for patients**
- First mover and 15+ years of development to create a plethora of spatial analytics algorithms and explainable AI models that are **adaptive and agnostic** to any imaging platform, any disease, and any multi-modal datasets
- **Solid moat** around the use of Explainable AI to capture tumor heterogeneity, cell typing, and microdomain discovery with **10+ patents** granted and expanding
- \$65B+ precision medicine market; early exit opportunity (~10-20X Return)
- Raised \$6.9M non-dilutive funding and pursued **milestone driven** seed rounds totaling \$7.6M from Keiretsu Capital, Keiretsu Forums (NW&R, N.Cal, London, Toronto), Newlin Investment Co., Innovation Works, Allegheny Health Network (AHN), Chemical Angel Network, and Sacramento Angels
- Partnerships with MD Anderson Cancer Center, UPMC, Univ. of Queensland
- Strategic partnerships: Fujifilm, Pictorlabs, SironaDx, iCura
- **www.predxbio.com | info@predxbio.com**



Propel IOT, LLC, Powered by AI

Name Richard L. Burtner, Founder, President & CEO
Address: P.O. Box 538.
Iron Station NC 28080
Phone: (c) 703-472-4707
Email: RickPropelGPSIOT@gmail.com

PROPEL IOT

Marrying GPS with IOT & AI “Power” for Customer Savings

Web Address: www.PropelGPS.com & www.PropelIOT.ai

Management: The team has built 3 prior \$100+M SaaS Co EVs, leading to exits with 100+ years of experience in this space. Inc. 500 CEO (SkyBitz), also has been a basement start-up Founder at Bluestar Communications that raised Silicon Valley VC funding, grew to a \$1.2BN IPO registration within 2 yrs. of Series A and sold to Covad for \$160M, plus other M&A deal expertise

Industry: IOT Powered by AI SaaS Asset Management Wireless Market

Number of Employees: 5 (incl. Member Mgr) + Consultants. 10 Former Team Members Joining Upon Series A Rd. Closing.

Year Company Founded: April 2022
Legal Structure: NC LLC, Converting to a C Corp at 12/31/24

Law Firm: Wyrick, Robbins Raleigh, NC. Larry Robbins, Our Acct. Partner

Financing to Date: \$5.5M
Financing 3 Yr. Plan: '25-'27

Equity Financing to Date:
Common Accredited Individual Investors
\$5.5M (Incl. Founder \$3+M)

Series A Round Financing:
Round Size: **\$3.5M (\$3M Institutional
\$500K Friends & Family Portion)**

Our Funding Ask: \$3.5M (\$3M Institutional & \$500K Friends & Family) Series A Equity Round

Business Description: Propel IOT provides affordable real-time movable asset management technology & information for SMB's better decision-making that leverages our patented SaaS GPS tracking & sensor monitoring platform powered by advancements in AI & IoT.

Refer to the Attached Page that Highlights the SMB CUSTOMER PROBLEM WE SOLVE; HOW WE SOLVE THIS SMB PROBLEM AND THE BENEFITS TO OUR SERIES A INVESTORS!

Value Proposition: We offer our SMB customers better service, better alternatives, and lower-priced solutions to improve efficiency and security with a compelling ROI. We also offer our investors a recurring revenue SaaS model with an efficient investment capital structure for exceptional IRR results.

Company Background: Our team has built 3 prior fast-growth SaaS businesses with over \$100+M Enterprise Values leading to exits. We have relevant market domain expertise, know customers plus their needs in our target markets & have already proven that our model works with revenue/marketplace acceptance. We have an entrepreneurial “Can Do” nimble customer focused & innovative Company culture, much like existed at prior successful entrepreneurial ventures that generated EXTRAORDINARY RESULTS such as SkyBitz (>50% compounded annual sales growth over 3-4 successive years when building to \$33MM revenue and over \$1M revenue per employee in Yr. 3 during the same period).

Products/Services: Refer to our website at www.PropelGPS.com. & www.PropelIOT.ai Additional solutions, product specification sheets, and summaries are available upon request.

Intellectual Property/Special Know- We have one granted patent and plans for five new provisional patents we will file during '25 once our Series A Round is completed. We expect that over the next 3 years, we will file additional patents as innovation warrants given our knowledge of our markets, innovative approach, and the strategic value creation that we recognize for our Company by filing patents that serve to add practical efficiency solutions for our SMB customers.

Markets: Our 3 Market Segments of Focus are Expected to Total \$2.2TR in '27. Serving SMBs are: (1.) Wide Area Supply Chain; (2.) Regional / Local Last-Mile Delivery Incl. Service Vans for Electrical, Plumbing, etc., and (3.) In Buildings at destinations such as Hospitals, Warehouses, etc. The CAGR of These Segments averages 10% per Year.

Sales and Marketing: We have 3 “sub-market segments” within Transportation, Logistics, and Telematics that we are pursuing. Our model is to have experienced sales professionals with whom our CEO has grown companies in the past join the Company incrementally as we grow. Currently, we have five dedicated employees. With the Series A Round, we will add ten more employees, most of whom have worked with our CEO. We will also add teaming partners & professional sales channel partner firms with experience in our targeted sub-markets to private label and/or promote our solutions. We also partner with a service-disabled veteran-owned small business as we pursue federal contracts.



The world's first AI powered, P2P car sharing marketplace for multi-residential communities.



At RideAlike, we believe accessing a ride should be as simple as connecting with a neighbour. That's why we launched the world's first peer-to-peer car-sharing platform tailored for multi-residential communities, allowing you to rent or swap vehicles with people just next door. Turn your parked car into extra income or find a convenient ride without leaving your building. By reducing the need for personal car ownership, RideAlike helps cut traffic congestion, maximize parking efficiency, and lower carbon emissions, making urban spaces more sustainable for everyone.

Challenge: Seizes multiple market challenges: builders and owners contend with increased construction costs and maintenance, vehicle owners incur high ownership costs, and renters deal with poor user experiences, limited vehicle selection, opaque pricing, and lengthy pickup and return processes in multi-residential communities.

Solution: Transforms urban transportation by reducing construction costs for builders, enabling owners to monetize idle cars with AI pricing, and providing renters 24/7 digital access to a diverse vehicle fleet with roadside assistance and upto \$2M insurance.

Business Model: Operates in a digital marketplace on iOS, Android, and Web, connecting guests & hosts. The company earns a 40% gross margin on transaction revenues, aligning its success with rental frequency and volume. Also, bringing a subscription model for both car owners & renters.

Competition: Peer to Peer: Turo, Getaround; Corporate Fleet: Enterprise, Budget, Avis, Zip Car, Kite Mobility; Community Owned: CommunAuto.

Differentiation: Differentiates itself by promoting multi-modal mobility through innovative, AI-enhanced solutions that foster community in high-rise residences, enabling Millennials & Gen Zs to conveniently share and swap cars, thereby building trust and enhancing efficiency, affordability, and sustainability.

Go To Market: The strategy targets multi-residential buildings, currently encompassing 10 buildings & over 3,000 units. This B2B2C approach benefits builders and residents, with pilot projects with the City of Markham and ongoing expansion discussions for 115 more buildings.

Traction YTD: 10 Highrise building contracts, 8,734 app downloads, 5,064 signups, 247 Cars, 3,643 rental days, \$235K USD gross revenue.

Financial Forecast (Gross Revenue):

- 2025: \$1,399,542
- 2026: \$3,532,737
- 2027: \$9,032,562
- 2028: \$23,735,655
- 2029: \$42,574,141

Exit: IPO or Potential acquisition by an OEM or US/foreign market leader.

Stage: Seed

Investment Opportunity: \$800K

Commitment Received: \$462K

Round Closing Date: March 31st, 2025

Funding to Date: \$672K by Founders and Grant

Use of Funds: 50% Marketing & Biz Dev, 25% Product Development and 25% Operations & Customer Success

Industry: PropTech, AutoTech, CleanTech
Market Size: \$86B, 304MM vehicle renters (Canada/US/UK/Europe)



Zelani Bhuiyan



Co-Founder & CEO

Digital Transformation & Product Mgt
BSc, Master of Business Entrepreneurship



Abeda Bhuiyan



Co-Founder & CFO

Financial Mgmt and Consulting
MBA, CPA, CA



Jamil Bilgin



COO

Operations & Growth Marketing
BA, MS in Marketing



Pratiksha



Product Management Lead

BA & MA in Economics, Masters in Business Analytics,

* Number of Employees: 8

**All \$ in USD



**“NOW”
OPPORTUNITIES
AVAILABLE!**

*“ONE UNIT of ownership in the LLC
could yield \$2-5M over 5 years!”*

<https://TESS.Energy>

TESS Energy Solutions
Thermal Energy Salvage/Storage & Conversion System
Bridge to Commissions from Sales pending!

**Unique in the World
Technology**
DECEMBER 5, 2024

UNIQUE Thermal Energy Salvage/Storage & Conversion: IP Licensing, Global Distributor moving to mass production.

TESS Energy Solutions is the Global Authorized Distributor and sole IP licensing Agent for TESS, with stake in the IP

- TESS reduces Energy consumption in large commercial and industrial facilities by 20-35%, which has been documented in \$50M worth of Canadian Generation 1-4 Research and Development deployments with zero hours of technology related downtime.
- TESS increases the output of all types of power generation 25-40%
- With Solar Thermal Concentrators, TESS can produce *20 mWh of power per day in less than half a football field.*
- TESS Energy Solutions has early \$200M worth of pilot projects in preliminary engineering / project analysis stages with companies like LyondellBasell, TATA Steel, Novelis Aluminum, Guardian Glass and more. The sales cycle is about 4-6 months long and some are just beginning but some are nearing contract phase.
- TESS helps clients decarbonize, meeting ESG environmental goals while enhancing profitability. However, a thorough engineering analysis is required to gauge the value of TESS to the facility.
- TESS Energy Solutions has just completed an APP, the results of almost \$2M investment, that allows us to do as many as 1000 such analyses per month, *where previously, manually we could only do 2-3/month.*

Our partner TECH CO-OP in Houston, whose Joseph Wilson made Controls for Baker Hughes for 34 years, will process standing job/shop orders and lead the transition to mass production plant to launch by Q2/3 2025. \$3B worth of product/year. CAP RAISE FOR PLANT WILL MERGE LLC INTO 60% CONTROL OF PLANT AND EXPANSION

M.P. Logan and Associates, LLC dba TESS Energy Solutions has 200 Membership Units (shares) Class A (voting); \$50,000 each and Class B (non-voting) \$35,000 each. There are TEN Class A and FOUR Class B available. Distributions for both classes are paid equally and same time. \$500,000 for TEN Class A Units, guarantee principle, 100% ROI likely by Q3 2025.

Profit distributions from the first 500 1MW contracts are expected to begin no later than Q3 of 2025.

Over five years, each unit will earn \$2-5M, and likely more.

The founder, and minority shareholder, set the company up to yield short-term and long-term gains. *Some of founder's profits will deploy TESS plus FOCUS solar thermal for the worlds' 2 billion people with no access to electricity.*



**TESS.ENERGY
SOLUTIONS**

Michael Logan, CEO
Tess Energy Solutions
844-589-3681
409-682-3881
MichaelLogan@TESS.energy

Our Partners



bwtech@UMBC

bwtech Research & Technology Park at UMBC is a dynamic innovation hub that supports companies at every stage of development—from concept to revenue growth. Through incubation, research partnerships, educational programs, expert mentorship, and strategic connections, bwtech empowers businesses to scale and succeed in Maryland and beyond. With over 500,000 square feet, bwtech offers state-of-the-art wet labs, offices, and meeting spaces tailored for tech-focused industries including AI, cybersecurity, environmental technologies, and life sciences. Learn more at bwtech.umbc.edu.



MODUS CREATE @ModusCreate

Modus Create is a digital transformation consulting firm dedicated to helping clients build competitive advantage through digital innovation. Our global team of strategists, designers, and technologists has helped the world's biggest brands deliver powerful experiences. We specialize in strategic consulting, full lifecycle product development, platform modernization, and digital operations. Our official partners include leading technology companies like Atlassian, AWS, Ionic and GitHub, providing clients unmatched capabilities across the full product development lifecycle.



NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior services across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



AEG

AEG is a values-based membership organization that creates personal and business growth through trusted relationships. As a "Time Machine" for business leaders, AEG accelerates trust and facilitates peer relationships to drive business development and personal growth. We connect three communities of midmarket CEOs, elite business advisors, and regional centers of influence. Through regular programs, education and community facilitation, AEG cultivates deep personal and business relationships, enabling fast, impactful connections, collaboration, and personal and business referrals.



BUZZY ROCKET

Buzzy Rocket was founded 12 years ago with the mission to help startups grow and scale their businesses. Debbie and Victoria do this with their decades of marketing experience combined with their first hand experience founding, growing and scaling successful startups. They only work with 6 startups at any given time so they can provide 1:1 attention to you and your team. The Buzzy Rocket team is also made up of web developers, graphic designers and copywriters so they can help you easily execute the marketing strategy you create. Learn more about their services at BuzzyRocket.com.

February 6 Attendees As of 02 07 25

SPEAKERS			
First Name	Last Name	Title	Company
Tien	Wong	Founder and Host	CONNECTpreneur
Aaron	Miscenich	Executive Director	bwtech@UMBC
John	Gilstrap	Assistant Secretary	Maryland Dept of COMMERCE
Pat	Sheridan	CEO	Modus Create
Anthony	Millin	Founder and Chair	NEXT powered by Shulman Rogers
Debbie	Cline	Founder & Chief of Client Success	Buzzy Rocket
Sara	Clasper	Associate Attorney	NEXT powered by Shulman Rogers

First Name	Last Name	Title	Company
Gib	Dunham	Director	ACTA Thermal Technologies
Mustafa	Al-Adhami, PhD	CEO	Astek Diagnostics Inc.
Matthew	Fonte, PhD	President	ColdSnap
Sam	Malhotra	CEO	ezVOLTz.com
Sheldon	Goldstein	CEO	Coagulation Sciences
Elizabeth	Smith, PhD MBA	Chief Business Officer	Fzata, Inc.
Steve	Willard	CEO	ICaPath Inc.
Frank	Turano	CRO	Natáur
B. Dusty	Majumdar, PhD	CEO	PredxBio
Rick	Burtner	Founder, President & CEO	Propel IOT
Zelani	Bhuyian	Co-founder & CEO	RideaLike
Michael	Logan	CEO	TESS Energy

ATTENDEES			
First Name	Last Name	Title	Company
Samer	Ahirrao	CEO	Ardent Privacy
Hafiz	Ahmed, PhD	CEO	GlycoMantra
Peter	Ajusten	CEO	AmeriTrust Solutions
Mustafa	Al-Adhami	CEO	Astek Diagnostics
Amy	Alkhalil		Towson University
Margo	Amrein	CFO	CliftonLarsonAllen
Will	Anderson	Strategic Consultant	bwtech
Alexander	Austin	President & CEO	Prince George's Chamber of Comm.
Stephen	Auvil	Chief Federal Engagement Officer	TEDCO
Marco	Avila	CEO	MD Hispanic Chamber of Comm.
Erika	Baez-Grimes	Sr. Business Broker	Transwestern Business Advisors
Kory	Bailey	CEO	UpSurge
David	Bain	President	TM Technologies
Ron	Baker	Chief Business Officer	20/20 Gene Systems
Ken	Barton	President and CEO	SafetySpect
Vippy	Bhambra	CEO	Glomo LLC
Rupesh	Bharad	President & CEO	Transworld Business Advisors
Mahesh	Bhatija	General Partner	Human Health Ventures
Chuck	Bieberic	Facutly	UMBC Facutly
Mike	Black	VP Defense	AFCEA
Dr. Brian	Block, MD PhD	Investor	Investor
Justin	Brodie-Kommit	General Partner	Symbiotic Earth Ventures
Ben	Broedel	CEO	Athena
Peter	Buchanan	Managing Partner	NewPlan, LLC
Mavis	Burks	Founding Partner	TwentyTwo Insights Advisory Group
Martin	Cadirola	CTO and VP Bus. Dev.	Ecotronics Ventures
Anthony	Cammarata	Founder/CEO	Startupcannon
Matt	Canning	Founder & CEO	NoPlex
Sue	Carr	President & CEO	CarrTech Corp.
Ryan	Carrroll	Senior Director	G-Squared Partners
Courtney	Cavin	Chief Product Officer	Astek Diagnostics
Tonia	Chagnon	Events Manager	AEG
Hao	Chen	Founder & CSO	DRI Biosciences
Chakra	Chennubhotla	Chief of AI, COO	PredxBio
Jeff	Cherry	Managing Partner	Conscious Venture Funds
Craig	Cinquina	Chief Commercial Officer	PredxBio
Orin	Clay	Managing Principal	JBOR GROUP CAPITAL
Joseph	Clayborne II	Entrepreneur	
Andrew	Comeau	Scientific Associate	Scheer Partners
Ed	Connors	CEO	Heudia
Tasha	Cornish	Executive Director	Cybersecurity Assn.
Marjorie	Cota	Dir. of Entrepreneurial Services	bwtech@UMBC
George	Davis	bwtech Board Member	Wexford SciTech Fund

Hector	Del Castillo	CPO	Byond
John	Dierkes	Managing Director	Pickwick Capital Partners
Rich	DiPippo	Partner	NFP
Graham	Dodge	VP of Venture Development	TEDCO
Lisa	Dorsey	Private Capital	Terra Nova Capital
Dean	Drake	Assoc. VP of Research at UMBC	UMBC
Jake	Drohat	Project Engineer	Northrup Grumman
Shelley	Dull	VP Sales	Propel IOT
Tom	Duquette	Director, Investor Relations	ColdSnap
Laura	Everngam-Price	Dir. of Strategic Partnerships	ezVOLTz
Chris	Ewing	bwtech EIR	bwtech
Herb	Ezrin	President	Potomac Business Group
Branda	Fan	CEO	NOWY
Hanping	Feng	CSO	Fzata, Inc.
David	Fink	bwtech EIR	bwtech
Keith	Fisher	Managing Director	G-Squared Partners
David	Fitzpatrick	VP, Marketing	Modus Create
Rachel	Foster	CEO	Hassun
Lucas	Franco	Research Scholar	UMB
Peter	Frantz	COO	Frantz Viral Therapeutics
Jeffrey	Freedman	Director	Startup Grind Maryland
Chris	Frew	Founder	BioBuzz
Kevin	Fulmer	Exec Director ABCE	UMBC
Francesca	Gallucci	Head of Commercial	Nataur LLC
Raina	Gandhi	Founder	Rising Tide Consulting
Vivek	Ganesh	CEO	Neurava
Duane	Gardner	Partner	GSR Partners
Jim	Gibbons	Founder	Alpha Pointe Capital
Jameson	Gibbons	Growth Ventures	Mindgrub
Joshua	Gilkin	Partner	NEXT powered by Shulman Rogers
Hillel	Glazer	bwtech EIR	bwtech
Andrew	Goldsmith	Partner	Mooring Partners
Lei	Gong	Event Assistant	CONNECTpreneur
Shawn	Green	President	MTEC
John	Gregg	CEO	BalinBac Therapeutics, Inc.
David	Gruber	SVP BD	Evergreen Advisors
Ajay	Gupta	Co-founder & CEO	HSR.health
Mark	Haas	CEO	AEG
Andrew	Haberman	Partner	ESF IP Law
Chris	Haug	Managing Director	Startup Grind Maryland
Natasha	Heidenrich	Director, Strategy	Astroport Space Technologies
Deb	Hemingway	Managing Partner	Ecphora Capital
Bradley	Hennessie	CEO	NextStep Robotics
David	Hernandez	Engagement Executive	Rootstack
Christina	Holt	bwtech EIR	bwtech
Helene	Huang	Founder	Stealth Tech Startup
Jeff	Huber	CFO	INNOLINGUA
Ric	Hughen	CEO	Linshom Medical
Doug	Humphrey	President	JETCO Research
Joyce	Hunter	Executive Director	Mission Critical
Debbie	Irwin	Managing Director	Lighthouse Labs
Benjamin	Israel	Founder and CEO	Juniper Health Systems
Tisha	Jepson	CEO	True Bearing Diagnostics
Frank	Johnson	Chief Strategy Officer	Space Phoenix Systems
Frank	Johnson	Chief Strategy Officer	Space Phoenix Systems
Suby	Joseph	President	Brandywine Insights
Fehmida	Kapadia	bwtech EIR	bwtech
Peter	Kaufman	CTO	ACTA-TechUS, Inc.
Lori	Kavle	Director, Marketing	SciTech Development
Ethan	Kazi	CEO	The Canton Group
Cam	Kelley	Managing Member	Clover Construction
John	Kennedy	CFO	ICaPath
Yoonseon	Kim	COO	CORESTEMCHEMON US
Dongmin	Kim	CEO	INNOLINGUA
Nigel	Knowles	CEO	Beyond Commissions
Nigel	Knowles	CEO	Beyond Commissions
Ted	Koblick	VP, Business Development	Net-AV
Marty	Koev	Head of Investments	Koev Brothers
Sotti	Koev	Co-Founder and Partner	Koev Brothers
Vijay	Lakshman	Chief Strategy Officer	Andrometa Inc.
Kevin	Lancaster	CEO	Channel Program
Leo	Lau	Co-Founder	NOWY

Ines	Lebow	CEO	Enterprise Transformation Solns
John	Lee	CEO	AKP Foundation
Matthew	Lee	CEO	FasTech
Sang	Lee	Exec. Asst.	ExoRenal
Troy	Lemaille-Stovall	CEO	TEDCO
Charis	Li		Johns Hopkins Carey Business School
Brock	Lindsey	Founder	ICaPath
Mel	Litter	CEO	Elemental Impact Solutions
Xiaonao	Liu	CEO	Nanobiofab
Winston	Lord	Founder	LORD Advisory
Jet	Lu	Customer Solutions	Amazon Web Services
Bei	Ma	CEO	The Pinea Group
Rodd	Macklin	General Partner	SaaS Ventures
Sunil	Madan		Investor
Neetu	Madan		Investor
Jeff	Majka	CEO	The Security Bulldog
Mike	Malloy	CEO	Malloy Industries
Karina	Mandell	CEO	Mandell Management
Jason	Mantzouranis		TN Americas
Ucheonye	Maple	President	Noteworthy Consulting
Todd	Marks	Founder & CEO	Mindgrub
Wendy	Martin	Dir., Technology Dev.	UMBC
TJ	Master	Technology Mentor	Virginia ICAP
Jay	McCrensky	CEO	Marketshare Management
Gordon	McKenzie	CEO	PostCare.AI
Brian	Meritt	Managing Director	Global Deployment Partners
Jomy	Methipara	Partner	Dickinson Wright
Len	Miller	CEO	Len Miller & Assoc.
Kay	Mok	Senior Partner	Gobi Ventures
Joe	Moorman	COO	Transworld Business Advisors
Alicia	Moran	Dir. Innovation & Eship	Prince Georges County EDC
John	Morgan	Principal	Morgan.Global
Maureen	Mulvihill	President & CEO	Actuated Medical
Ian	Nabb	Managing Partner	1219 Capital Partners
Charlie	Nahabedian	CEO	VK Digital Health
Silvana	Nani	CEO	Korabi Consulting
Laura	Neuman	CEO	Neuman Strategy
Mike	Niggel	CEO	ACT-1 Federal
Naa	Nyanin	CEO	NDN International
IB	Olajid	Program Intern	bwtech
Joe	O'Rourke	Banker	J.P. Morgan
Alejandro	Oses	CEO	Rootstack
Jean-Luc	Park	Sr Director Social Impact Funds	TEDCO
Jay	Park	Managing Partner	Linkorus, LLC.
Isabella	Penfiel	Engineer	Astek Diagnostics
Mike	Petry	Partner	KPMG
Zach	Pogue	Venture Partner	IronGate Capital
Sean	Powell	VP, State & Local Governments	ezVOLTz
Maureen	Pugh	Entrepreneurial Svcs Program Mgr	bwtech
Filippo	Pullara	CSO	PredxBio
Alexa	Raad	CMO and Cyber	Propel IOT
Gary	Rahman	Managing Member	QLI L.L.C.
Kinneret	Rand-Yadin, Ph.D.	Founder and CEO	SeeTrue Technology, LLC
Maureen	Reese	Principal	Korn Ferry
Abhishek	Rege	Founder	Vasoptic Medical
Tim	Reyna	CIO/CTO	AFCEA
Alexander	Reynolds	Owner	Hippogriff Consulting
Patrick	Rockhill	Director	Startup Grind Maryland
Ravenna	Roso	Marketing Manager	InfoPathways
Chris	Ross	Managing Director	Wilmington Trust
Dev	Roy		
Boyd	Rutherford	Partner	Davis, Agnor, Rapaport & Skalny
Dipanjan	Saha	CEO	Spyre Technologies
John	Sanwo	Founder/CEO	WearableDose, Inc.
Daniel	Saragnese	CEO	SereNeuro
Surjodeep	Sarkar	COO	PostCare.AI
Andrew	Schaefer	Project Manager	Congruence Medical Solutions
Andrew	Schaefer	Project Manager	Congruence Medical Solutions
David	Schaffer	Partner	BDM Collective
Alec	Schapiro	Sales Manager	InfoPathways
Michael	Schwartz	Vice President	JP Morgan Private Client
Joe	Serafin	Owner & Principal Broker	Serafin Real estate

Prashant	Shah	President	CloudLeap Technologies
Scott	Shepherd	Innovation Activation Manager	JLABS
Robert	Sherry	Advisor	Blackcomb Media Advisors
Gautan	Shetty	CEO	Congruence Medical Solutions
Gautan	Shetty	CEO	Congruence Medical Solutions
Zorawar	Singh	Intern	Potomac Business Group
Chris	Skipwith	CSO	Astek Diagnostics
Sharif	Small	Director of Entrepreneurship	Greater Baltimore Urban League
Elizabeth	Smith	Chief Business Officer	Fzata, Inc.
Todd	Smith	Founder and CEO	Haptic
Anthony	Solazzo	Managing Partner	Masonboro Partners
Tom	Solitario	Founder and CEO	Tom, Inc.
Bjorn	Song	CEO	Song Biotechnologies
Chris	Steele	Chief Strategy Officer	MTEC
Ayinde	Stewart	bwtech Board Member	bwtech Board
Greg	Stone	Partner	Whiteford
Bob	Storey	Managing Partner	LaunchPort, LLC
Angelo	Thalassinidis	Co-Founder	GDG Annapolis
Sam	Tomlinson	Director	W Ventures
Kathleen	Turano	President/COO	Nataur LLC
Nancy	Tyagi	CTO	PostCare.AI
Carol	Van Cleef	CEO	Luminous Group
Mark	VanderZyl	Director, Connect Labs Baltimore	Wexford Science & Technology
Gary	Wakeford	CEO	SonoStik LLC
Jun	Wang	CEO	Phycin, Inc.
John	Warden	CEO	Hememics Biotechnologies
David	Warschawski	Managing Partner	W Ventures
Joseph	Weaver	President	Global Design Interactive
Bosith	Weerasinghe	CEO	Bon Voyage
Barry	Weinbaum	Financial Services Professional	New York Life
Lauren	Weinberg	Marketing Manager	bwtech
Irving	Weinberg	President	Weinberg Medical Physics
Natalia	Wesson	Senior VP	Bank of America
Chris	White	bwtech EIR	bwtech
Laurie	Wiggins	CEO	Byond
Norelle	Wildburger	CEO	Nanost
Adam	Woodward	Partner	unMBA
Vennard	Wright	CEO	PerVista
Nancy	Wu	Advisor	Opus8
Nkozia	X	Founder	UABES
Zhiyong	Yang	CEO	Fzata, Inc.
Michael	Yukas	Registered Representative	New York Life
Juliet	Zon	MD	Johns Hopkins University
Karen	Zuccardi	Ecosystem Director	TEDCO

Thank you to our Partners



Thank You to our Host Committee



Marco Avila

WSP/MD Hispanic Chamber
of Commerce



John Dierkes

Pickwick Capital Partners



Matthew Lee

FASTech, Inc.



**Erika Baez-
Grimes**

Transworld
Business Advisors



Chris Frew

BioBuzz



Karina Mandell

Mandell Management



Jeff Cherry

Conscious Venture Partners



James Gibbons

Alpha Pointe Capital



Len Miller

Leonard J. Miller &
Associates



Tasha Cornish

Cybersecurity
Association Inc.



Chris Haug

bwtech@UMBC Research
and Technology Park



Laura Neuman

NextGen Venture Partners



George Davis

Wexford SciTech Venture
Fund



**Deborah
Hemingway**

Ecphora Capital



Chris Ross

Wilmington Trust

SHOUTOUT TO OUR PREP TEAM



Big Idea CONNECTpreneur

**REGISTER FOR OUR
UPCOMING VIRTUAL
EVENT!**

February 27



**REGISTER FOR OUR
NEXT IN-PERSON
EVENT**

March 19



**VIEW A LIST OF ALL
RSVPS FOR TODAY'S
EVENT HERE!**



DRIVING DIGITAL INNOVATION WITH MEANINGFUL OUTCOMES



Modus Create is an end-to-end digital consulting firm. We bring multiple integrated skill sets and methodology expertise across software, product, and commercial platform domains. Our clients experience a boutique feel on an enterprise scale.

Our Practices and Offerings

DIGITAL STRATEGY

Making intelligent decisions about investments in technology.

PRODUCT DEVELOPMENT

Building and enabling business-aligned applications that deliver stakeholder and customer value.

PLATFORM & CLOUD

Adopt a modern platform mindset, with scalable and secure architectures, tooling, and systems to increase quality and speed.

DIGITAL OPERATIONS

Operationalize collaboration, drive alignment in a single system of truth, and adopt modern methodologies for teamwork.

All four practice areas are powered by **AI & DATA** expertise throughout



Whether you're looking to innovate, scale, or transform, our team brings the right methodology and skill sets to drive your success.

Let's build the future together.
Contact us today to get started!





VIRTUAL AND IN-PERSON

CALL FOR PRESENTERS

Unprecedented
**Networking
sessions**
before, during, and
after each event

Free lifetime
admission
to all
CONNECTpreneur
Forums

Post-event recap to
**206k business
leaders**
in our Community

SCAN HERE FOR
THE IN-PERSON
BROCHURE:



SCAN HERE FOR
THE VIRTUAL
BROCHURE:



Get funded with our



Private Investor Platform



One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

**Exclusive,
cost effective,
& reliable**

**Vetted, qualified,
accredited
Investors**

**We
guarantee
our results**



**View the full
brochure**

Tien Wong
CEO
twong@opus8.com

Skylar Rallison
Community Manager
srallison@opus8.com

CONNECT with us!

